Kiniksa Pharmaceuticals Ltd
General ticker "KNSA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.5B
Kiniksa Pharmaceuticals Ltd follows the US Stock Market performance with the rate: 43.7%.
Estimated limits based on current volatility of 1.7%: low 20.07$, high 20.75$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [13.61$, 25.71$]
- 2024-12-30 to 2025-12-30 estimated range: [13.23$, 25.42$]
Financial Metrics affecting the KNSA estimates:
- Negative: Non-GAAP EPS, $ of -0.36 <= 0.10
- Negative: Operating profit margin, % of -8.53 <= 1.03
- Negative: Operating cash flow per share per price, % of 1.09 <= 2.35
- Positive: Interest expense per share, $ of 0 <= 0
- Positive: -0.96 < Investing cash flow per share, $ of -0.42
- Negative: Inventory ratio change, % of 6.06 > 1.08
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -0.25 < Return on assets ratio (scaled to [-100,100]) of 2.61
Short-term KNSA quotes
Long-term KNSA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $38.54MM | $220.18MM | $270.26MM |
| Operating Expenses | $195.18MM | $210.41MM | $295.45MM |
| Operating Income | $-156.64MM | $9.77MM | $-25.20MM |
| Non-Operating Income | $0.10MM | $1.25MM | $8.54MM |
| Interest Expense | $0.00MM | $1.25MM | $0.00MM |
| R&D Expense | $99.30MM | $65.49MM | $76.10MM |
| Income(Loss) | $-156.54MM | $11.03MM | $-16.65MM |
| Taxes | $1.39MM | $-172.34MM | $-30.74MM |
| Profit(Loss) | $-157.92MM | $183.36MM | $14.08MM |
| Stockholders Equity | $185.04MM | $396.15MM | $438.84MM |
| Inventory | $3.67MM | $21.60MM | $31.12MM |
| Assets | $232.80MM | $459.67MM | $526.32MM |
| Operating Cash Flow | $-126.30MM | $5.81MM | $13.30MM |
| Capital expenditure | $20.41MM | $0.10MM | $0.13MM |
| Investing Cash Flow | $128.63MM | $-8.08MM | $-29.56MM |
| Financing Cash Flow | $5.88MM | $2.52MM | $1.50MM |
| Earnings Per Share* | $-2.30 | $2.64 | $0.20 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.